Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BSTCNASDAQ:BYSIOTCMKTS:IPHYFNASDAQ:UROVNASDAQ:XENE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBSTCBioSpecifics Technologies$88.53$88.47$42.00▼$89.15$650.25M0.2461,105 shsN/ABYSIBeyondSpring$2.25-1.7%$2.09$0.98▼$3.44$89.90M0.1732,173 shs15,121 shsIPHYFInnate Pharma$1.95$1.59$1.45▼$1.95$163.47M0.565 shsN/AUROVUrovant Sciences$16.24$16.23$7.15▼$16.26$531.75M2.36114,469 shsN/AXENEXenon Pharmaceuticals$34.70+4.0%$32.48$26.74▼$46.00$2.55B1.1632,096 shs492,450 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBSTCBioSpecifics Technologies0.00%0.00%0.00%0.00%0.00%BYSIBeyondSpring0.00%-8.16%+33.53%+67.91%-8.91%IPHYFInnate Pharma0.00%0.00%+34.48%-32.76%-21.69%UROVUrovant Sciences0.00%0.00%0.00%0.00%0.00%XENEXenon Pharmaceuticals0.00%+7.11%+12.93%+18.04%-3.92%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBSTCBioSpecifics TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ABYSIBeyondSpringN/AN/AN/AN/AN/AN/AN/AN/AIPHYFInnate PharmaN/AN/AN/AN/AN/AN/AN/AN/AUROVUrovant SciencesN/AN/AN/AN/AN/AN/AN/AN/AXENEXenon Pharmaceuticals2.918 of 5 stars4.52.00.00.01.22.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBSTCBioSpecifics Technologies 0.00N/AN/AN/ABYSIBeyondSpring 0.00N/AN/AN/AIPHYFInnate Pharma 0.00N/AN/AN/AUROVUrovant Sciences 0.00N/AN/AN/AXENEXenon Pharmaceuticals 3.00Buy$54.8257.96% UpsideCurrent Analyst Ratings BreakdownLatest XENE, UROV, BSTC, IPHYF, and BYSI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025XENEXenon PharmaceuticalsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$55.005/13/2025XENEXenon PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$50.00 ➝ $47.005/13/2025XENEXenon PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$58.00 ➝ $55.005/13/2025XENEXenon PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$53.00 ➝ $53.005/13/2025XENEXenon PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$55.00 ➝ $55.005/13/2025XENEXenon PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$60.00 ➝ $55.005/7/2025XENEXenon PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$55.005/5/2025XENEXenon PharmaceuticalsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform4/17/2025XENEXenon PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$60.00 ➝ $52.00(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBSTCBioSpecifics Technologies$38.19M17.03$3.38 per share26.18$18.42 per share4.81BYSIBeyondSpring$1.75M51.84N/AN/A($0.37) per share-6.08IPHYFInnate Pharma$21.77M7.51N/AN/A$0.11 per share17.73UROVUrovant SciencesN/AN/AN/AN/A($1.90) per shareN/AXENEXenon Pharmaceuticals$7.50M355.06N/AN/A$9.90 per share3.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBSTCBioSpecifics Technologies$24.47M$3.3337.5117.60N/A47.43%14.81%14.46%N/ABYSIBeyondSpring-$11.12MN/A0.00∞N/AN/AN/AN/AN/AIPHYFInnate Pharma-$53.53MN/A0.00∞N/AN/AN/AN/A9/17/2025 (Estimated)UROVUrovant Sciences-$146.74M-$4.71N/AN/AN/AN/AN/A-162.90%N/AXENEXenon Pharmaceuticals-$234.33M-$3.23N/AN/AN/AN/A-32.44%-30.84%8/14/2025 (Estimated)Latest XENE, UROV, BSTC, IPHYF, and BYSI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025BYSIBeyondSpringN/A-$0.06N/A$0.11N/AN/A5/12/2025Q1 2025XENEXenon Pharmaceuticals-$0.90-$0.83+$0.07-$0.83$1.64 million$7.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBSTCBioSpecifics TechnologiesN/AN/AN/AN/AN/ABYSIBeyondSpringN/AN/AN/AN/AN/AIPHYFInnate PharmaN/AN/AN/AN/AN/AUROVUrovant SciencesN/AN/AN/AN/AN/AXENEXenon PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBSTCBioSpecifics TechnologiesN/A66.2466.24BYSIBeyondSpringN/A2.492.49IPHYFInnate PharmaN/A2.602.60UROVUrovant SciencesN/A2.912.91XENEXenon PharmaceuticalsN/A17.6617.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBSTCBioSpecifics Technologies60.34%BYSIBeyondSpring40.29%IPHYFInnate PharmaN/AUROVUrovant Sciences18.44%XENEXenon Pharmaceuticals95.45%Insider OwnershipCompanyInsider OwnershipBSTCBioSpecifics Technologies15.70%BYSIBeyondSpring29.31%IPHYFInnate Pharma31.89%UROVUrovant Sciences2.70%XENEXenon Pharmaceuticals5.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBSTCBioSpecifics Technologies77.35 millionN/ANot OptionableBYSIBeyondSpring8040.32 million28.50 millionOptionableIPHYFInnate Pharma17983.83 million57.10 millionNot OptionableUROVUrovant Sciences7032.74 millionN/ANot OptionableXENEXenon Pharmaceuticals21076.73 million72.50 millionOptionableXENE, UROV, BSTC, IPHYF, and BYSI HeadlinesRecent News About These CompaniesXenon Pharmaceuticals (NASDAQ:XENE) Shares Cross Below 200 Day Moving Average - Here's WhyJuly 5 at 4:26 AM | marketbeat.comXenon Appoints CEO Ian Mortimer as Interim CFOJuly 3 at 6:32 PM | tipranks.comXenon Pharmaceuticals Inc. Added to Russell 3000® and Russell 2000® Indexes in Annual Reconstitution - NasdaqJune 29, 2025 | nasdaq.comXenon Pharmaceuticals Joins Russell 3000® and 2000® IndexesJune 27, 2025 | tipranks.comXenon Pharmaceuticals Inc. Added to Russell 3000® and Russell 2000® Indexes in Annual ReconstitutionJune 27, 2025 | quiverquant.comQXenon Joins the Russell 3000® and Russell 2000® IndexesJune 27, 2025 | financialpost.comFXenon Joins the Russell 3000® and Russell 2000® IndexesJune 27, 2025 | globenewswire.comXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 26, 2025 | financialpost.comFXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 26, 2025 | globenewswire.comXenon Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:XENE)June 26, 2025 | marketbeat.comXenon Pharmaceuticals (NASDAQ:XENE) Share Price Passes Below 50 Day Moving Average - What's Next?June 25, 2025 | marketbeat.comXenon Announces Appointment of Darren Cline as Chief Commercial OfficerJune 24, 2025 | globenewswire.comXenon Pharmaceuticals (NASDAQ:XENE) Stock Price Down 3.4% - Here's WhyJune 16, 2025 | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Average Recommendation of "Buy" from AnalystsJune 15, 2025 | marketbeat.comTraders Purchase High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)June 12, 2025 | marketbeat.comXenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue?June 11, 2025 | zacks.comCantor Fitzgerald Estimates XENE FY2026 EarningsJune 10, 2025 | marketbeat.comXenon to Present at the Goldman Sachs 46th Annual Global Healthcare ConferenceJune 3, 2025 | globenewswire.comXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 30, 2025 | globenewswire.comFair Value analysis proves accurate as XENE drops 37% from February 2024 peakMay 21, 2025 | investing.comWhy Xenon Pharmaceuticals Inc. (XENE) Declined on TuesdayMay 15, 2025 | insidermonkey.comMedia Sentiment Over TimeXENE, UROV, BSTC, IPHYF, and BYSI Company DescriptionsBioSpecifics Technologies NASDAQ:BSTCBioSpecifics Technologies Corp., a biopharmaceutical company, develops an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX and Xiapex brands. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis, human lipoma, and uterine fibroids. The company has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Wilmington, Delaware.BeyondSpring NASDAQ:BYSI$2.25 -0.04 (-1.75%) As of 07/3/2025 01:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.Innate Pharma OTCMKTS:IPHYF$1.95 0.00 (0.00%) As of 07/3/2025Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.Urovant Sciences NASDAQ:UROVUrovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions in the United States. The company's lead product candidate is vibegron, an oral small molecule beta-3 agonist for the treatment of overactive bladder (OAB), OAB in men with benign prostatic hyperplasia, and abdominal pain due to irritable bowel syndrome. It is also developing URO-902, a gene therapy for patients with OAB who have failed oral pharmacological therapy. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. Urovant Sciences Ltd. was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.Xenon Pharmaceuticals NASDAQ:XENE$34.70 +1.33 (+4.00%) As of 07/3/2025 02:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
